iScience (Nov 2022)

A novel NF2 splicing mutant causes neurofibromatosis type 2 via liquid-liquid phase separation with large tumor suppressor and Hippo pathway

  • Zexiao Jia,
  • Shuxu Yang,
  • Mengyao Li,
  • Zhaoying Lei,
  • Xue Ding,
  • Mingjie Fan,
  • Dixian Wang,
  • Dajiang Xie,
  • Hui Zhou,
  • Yue Qiu,
  • Qianqian Zhuang,
  • Dan Li,
  • Wei Yang,
  • Xuchen Qi,
  • Xiaohui Cang,
  • Jing-Wei Zhao,
  • Wenqi Wang,
  • Aifu Lin,
  • Qingfeng Yan

Journal volume & issue
Vol. 25, no. 11
p. 105275

Abstract

Read online

Summary: Neurofibromatosis type 2 is an autosomal dominant multiple neoplasia syndrome and is usually caused by mutations in the neurofibromin 2 (NF2) gene, which encodes a tumor suppressor and initiates the Hippo pathway. However, the mechanism by which NF2 functions in the Hippo pathway isn’t fully understood. Here we identified a NF2 c.770-784del mutation from a neurofibromatosis type 2 family. MD simulations showed that this mutation significantly changed the structure of the F3 module of the NF2-FERM domain. Functional assays indicated that the NF2 c.770-784del variant formed LLPS in the cytoplasm with LATS to restrain LATS plasma membrane localization and inactivated the Hippo pathway. Besides, this deletion partly caused a skipping of exon 8 and reduced the protein level of NF2, collectively promoting proliferation and tumorigenesis of meningeal cells. We identified an unrecognized mechanism of LLPS and splicing skipping for the NF2-induced Hippo pathway, which provided new insight into the pathogenesis of neurofibromatosis type 2.

Keywords